RÉSUMÉ
Although phytochemicals are plant-derived toxins that are primarily produced as a form of defense against insects or microbes, several lines of study have demonstrated that the phytochemical, quercetin, has several beneficial biological actions for human health, including antioxidant and inflammatory effects without side effects. Quercetin is a flavonoid that is widely found in fruits and vegetables. Since recent studies have demonstrated that quercetin can modulate neuronal excitability in the nervous system, including nociceptive sensory transmission via mechanoreceptors and voltage-gated ion channels, and inhibit the cyclooxygenase-2-cascade, it is possible that quercetin could be a complementary alternative medicine candidate; specifically, a therapeutic agent against nociceptive and pathological pain. The focus of this review is to elucidate the neurophysiological mechanisms underlying the modulatory effects of quercetin on nociceptive neuronal activity under nociceptive and pathological conditions, without inducing side effects. Based on the results of our previous research on trigeminal pain, we have confirmed in vivo that the phytochemical, quercetin, demonstrates (i) a local anesthetic effect on nociceptive pain, (ii) a local anesthetic effect on pain related to acute inflammation, and (iii) an anti-inflammatory effect on chronic pain. In addition, we discuss the contribution of quercetin to the relief of nociceptive and inflammatory pain and its potential clinical application.
Sujet(s)
Composés phytochimiques , Quercétine , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Quercétine/composition chimique , Humains , Animaux , Composés phytochimiques/pharmacologie , Composés phytochimiques/usage thérapeutique , Composés phytochimiques/composition chimique , Douleur/traitement médicamenteux , Douleur nociceptive/traitement médicamenteux , Analgésiques/pharmacologie , Analgésiques/usage thérapeutique , Analgésiques/composition chimique , Inflammation/traitement médicamenteux , Nociception/effets des médicaments et des substances chimiques , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique , Anti-inflammatoires/composition chimiqueRÉSUMÉ
Pain and inflammation contribute immeasurably to reduced quality of life, yet modern analgesic and anti-inflammatory therapeutics can cause dependence and side effects. Here, we screened 1444 plant extracts, prepared primarily from native species in California and the United States Virgin Islands, against two voltage-gated K+ channels - T-cell expressed Kv1.3 and nociceptive-neuron expressed Kv7.2/7.3. A subset of extracts both inhibits Kv1.3 and activates Kv7.2/7.3 at hyperpolarized potentials, effects predicted to be anti-inflammatory and analgesic, respectively. Among the top dual hits are witch hazel and fireweed; polymodal modulation of multiple K+ channel types by hydrolysable tannins contributes to their dual anti-inflammatory, analgesic actions. In silico docking and mutagenesis data suggest pore-proximal extracellular linker sequence divergence underlies opposite effects of hydrolysable tannins on different Kv1 isoforms. The findings provide molecular insights into the enduring, widespread medicinal use of witch hazel and fireweed and demonstrate a screening strategy for discovering dual anti-inflammatory, analgesic small molecules.
Sujet(s)
Analgésiques , Anti-inflammatoires , Extraits de plantes , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/composition chimique , Analgésiques/pharmacologie , Analgésiques/composition chimique , Animaux , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Humains , Souris , Coriandrum/composition chimique , Simulation de docking moléculaire , Plantes médicinales/composition chimique , Inhibiteurs des canaux potassiques/pharmacologie , Inhibiteurs des canaux potassiques/composition chimique , Mâle , Tanins/pharmacologie , Tanins/composition chimiqueRÉSUMÉ
BACKGROUND: The Scutellaria genus has promising therapeutic capabilities as an aromatherapy. Based on that and local practices of S. nuristanica Rech. F. The essential oil was studied for the first time for its diverse biomedical applications. PURPOSE: This study aimed to evaluate and validate their therapeutic capabilities by screening the essential oil ingredients and examining their antimicrobial, antioxidant, carbonic anhydrase, and antidiabetic using further In silico assessment and In vivo anti-inflammatory and analgesic capabilities to devise novel sources as natural remedies alternative to the synthetic drugs. METHODS: Essential oil was obtained through hydrodistillation, and the constituents were profiled using GC-MS. The antimicrobial assessment was conducted using an agar well diffusion assay. Free radical scavenging capabilities were determined by employing DPPH and ABTS assay. The carbonic anhydrase-II was examined using colorimetric assay, while the antidiabetic significance was performed using α-Glucosidase assay. The anti-inflammatory significance was examined through carrageenan-induced paw edema, and the analgesic features of the essential oil were determined using an acetic acid-induced writhing assay. RESULTS: Fifty constituents were detected in S. nuristanica essential oil (SNEO), contributing 95.93 % of the total EO, with the predominant constituents being 24-norursa-3,12-diene (10.12 %), 3-oxomanoyl oxide (9.94 %), methyl 7-abieten-18-oate (8.85 %). SNEO presented significance resistance against the Gram-positive bacterial strains (GPBSs), Bacillus atrophaeus and Bacillus subtilis, as compared to the Salmonella typhi and Klebsiella pneumoniae, Gram-negative bacterial strains (GNBSs) as well as two fungal strains Aspergillus parasiticus and Aspergillus niger associated with their respective standards. Considerable free radical scavenging capacity was observed in DPPH compared to the ABTS assay when correlated with ascorbic acid. In addition, when equated with their standards, SNEO offered considerable in vitro carbonic anhydrase II and antidiabetic capabilities. Additionally, the antidiabetic behavior of the 9 dominant compounds of SNEO was tested via In silico techniques, such as molecular docking, which assisted in the assessment of the significance of binding contacts of protein with each chemical compound and pharmacokinetic evaluations to examine the drug-like characteristics. Molecular dynamic simulations at 100 ns and binding free energy evaluations such as PBSA and GBSA models explain the molecular mechanics and stability of molecular complexes. It was also observed that SNEO depicted substantial anti-inflammatory and analgesic capabilities. CONCLUSION: Hence, it was concluded that the SNEO comprises bioactive ingredients with biomedical significance, such as anti-microbial, antioxidant, CA-II, antidiabetic, anti-inflammatory, and analgesic agents. The computational validation also depicted that SNEO could be a potent source for the discovery of anti-diabetic drugs.
Sujet(s)
Anti-inflammatoires , Antioxydants , Oedème , Hypoglycémiants , Huile essentielle , Scutellaria , Animaux , Scutellaria/composition chimique , Antioxydants/pharmacologie , Antioxydants/composition chimique , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/composition chimique , Huile essentielle/pharmacologie , Huile essentielle/composition chimique , Hypoglycémiants/pharmacologie , Hypoglycémiants/composition chimique , Oedème/traitement médicamenteux , Analgésiques/pharmacologie , Analgésiques/composition chimique , Mâle , Souris , Simulation de docking moléculaire , Carragénane , Chromatographie gazeuse-spectrométrie de masse , Anti-infectieux/pharmacologie , Anti-infectieux/composition chimique , Aromathérapie/méthodes , Antibactériens/pharmacologie , Antibactériens/composition chimiqueRÉSUMÉ
This study investigates the anti-inflammatory, analgesic, and antioxidant properties of polyphenols extracted from Brassica oleracea var. capitata (cabbage) ethanolic extract (BOE). Given the historical use of cabbage in traditional medicine for treating various ailments, this research aims to validate these effects scientifically. The study involved the characterization of BOE's bioactive compounds using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography-Diode Array Detection-Electro-Spray Ionization Mass Spectrometry (HPLC-DAD-ESI MS) analysis. We assessed the anti-inflammatory and analgesic effects of topical and oral BOE administration on rodent models with acute and subacute inflammation. Additionally, the antioxidant capacity of orally administered BOE was evaluated. The results showed that BOE possesses significant levels of phenolic compounds with a potent antioxidant activity. The topical administration of BOE demonstrated notable anti-inflammatory effects in the tested rodent models, which were comparable with nonsteroidal anti-inflammatory drugs. These findings suggest that BOE could be a valuable natural remedy for inflammation-related conditions, supporting its traditional uses and highlighting its potential for further pharmacological development.
Sujet(s)
Analgésiques , Anti-inflammatoires , Antioxydants , Brassica , Inflammation , Extraits de plantes , Polyphénols , Animaux , Polyphénols/pharmacologie , Polyphénols/composition chimique , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Antioxydants/pharmacologie , Antioxydants/composition chimique , Brassica/composition chimique , Analgésiques/pharmacologie , Analgésiques/composition chimique , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/composition chimique , Inflammation/traitement médicamenteux , Souris , Rats , Mâle , Modèles animaux de maladie humaineRÉSUMÉ
German chamomile (Matricaria chamomilla L.) is an essential oil- containing medicinal plant used worldwide. The aim of this study was to gain knowledge of the phytochemical composition and the analgesic and soporific activity of Matricaria chamomilla L. (German chamomile) flower extract and its amino acid preparations, to predict the mechanisms of their effects by molecular docking and to develop aqueous printing gels and novel 3D-printed oral dosage forms for the flower extracts. In total, 22 polyphenolic compounds and 14 amino acids were identified and quantified in the M. chamomilla extracts. In vivo animal studies with rodents showed that the oral administration of such extracts revealed the potential for treating of sleep disorders and diseases accompanied by pain. Amino acids were found to potentiate these effects. Glycine enhanced the analgesic activity the most, while lysine and ß-alanine improved the soporific activity. The molecular docking analysis revealed a high probability of γ-aminobutyric acid type A (GABAA) and N-methyl-D-aspartate (NMDA) receptor antagonism and 5-lipoxygenase (LOX-5) inhibition by the extracts. A polyethylene oxide (PEO)-based gel composition with the M. chamomilla extracts was proposed for preparing a novel 3D-printed dosage form for oral administration. These 3D-printed extract preparations can be used, for example, in dietary supplement applications.
Sujet(s)
Acides aminés , Fleurs , Matricaria , Simulation de docking moléculaire , Composés phytochimiques , Extraits de plantes , Impression tridimensionnelle , Extraits de plantes/composition chimique , Extraits de plantes/pharmacologie , Animaux , Matricaria/composition chimique , Acides aminés/composition chimique , Fleurs/composition chimique , Composés phytochimiques/composition chimique , Composés phytochimiques/pharmacologie , Rats , Analgésiques/composition chimique , Analgésiques/pharmacologie , Mâle , SourisRÉSUMÉ
The effective management of moderate to severe pain often relies on the use of analgesic agents. However, the widespread utility of these medications is hindered by the occurrence of several undesirable side effects. In light of this challenge, there is growing interest in the development of κ opioid receptor (KOR) agonists, which have shown promise in mitigating these adverse effects. In this study, leveraging the structural scaffold of compound D (our previous study), we embarked on the design, synthesis, and evaluation of a series of N'-benzyl-3-chloro-N- ((1S,3R,4R)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl)benzenesulfonamide derivatives. These compounds were subjected to comprehensive in vitro and in vivo test. Through systematic structure-activity relationship (SAR) exploration, we successfully identified compound 23p (Ki(KOR):1.9 nM) as a highly selective KOR ligand of new chemotype. 23p showed high clearance in vitro PK test, and abdominal contraction test showed potent antinociceptive effect. 23p and its O-demethyl metabolite 25 were both found in the plasma of mouse, 25 also showed potent affinity toward KOR (Ki(KOR): 3.1 nM), both they contribute to the analgesic effect. Moreover, 23p exhibited potent antinociceptive activity in abdominal constriction test, which was effectively abolished by pre-treatment of nor-BNI, a selective KOR antagonist.
Sujet(s)
, Récepteur kappa , Sulfonamides , Animaux , Relation structure-activité , Sulfonamides/composition chimique , Sulfonamides/pharmacologie , Sulfonamides/synthèse chimique , Ligands , Récepteur kappa/métabolisme , Récepteur kappa/antagonistes et inhibiteurs , Souris , Mâle , Structure moléculaire , Humains , Découverte de médicament , Relation dose-effet des médicaments , Analgésiques/pharmacologie , Analgésiques/composition chimique , Analgésiques/synthèse chimique , RatsRÉSUMÉ
Soluble epoxide hydrolase (sEH) and HDAC6 mediate the NF-κB pathway in inflammatory responses, and their inhibitors exhibit powerful anti-inflammatory and analgesic activities in treating both inflammation and pain. Therefore, a series of dual-targeting inhibitors containing urea or squaramide and hydroxamic acid moieties were designed and synthesized, and their role as a new sEH/HDAC6 dual-targeting inhibitor in inflammatory pain was evaluated in a formalin-induced mice model and a xylene-induced mouse ear swelling model. Among them, compounds 28g and 28j showed the best inhibitory and selectivity of sEH and HDAC6. Compound 28g had satisfactory pharmacokinetic characteristics in rats. Following administration at 30 mg/kg, compound 28g exhibited more effective analgesic activity than either an sEH inhibitor (GL-B437) or an HDAC6 inhibitor (Rocilinostat) alone and coadministration of both inhibitors. Thus, these novel sEH/HDAC6 dual-targeting inhibitors exhibited powerful analgesic activity in nociceptive behavior and are worthy of further development.
Sujet(s)
Analgésiques , Conception de médicament , Epoxide hydrolase , Histone deacetylase 6 , Inhibiteurs de désacétylase d'histone , Inflammation , Douleur , Animaux , Histone deacetylase 6/antagonistes et inhibiteurs , Histone deacetylase 6/métabolisme , Douleur/traitement médicamenteux , Souris , Inflammation/traitement médicamenteux , Analgésiques/synthèse chimique , Analgésiques/pharmacologie , Analgésiques/usage thérapeutique , Analgésiques/pharmacocinétique , Analgésiques/composition chimique , Mâle , Inhibiteurs de désacétylase d'histone/synthèse chimique , Inhibiteurs de désacétylase d'histone/pharmacologie , Inhibiteurs de désacétylase d'histone/composition chimique , Inhibiteurs de désacétylase d'histone/usage thérapeutique , Inhibiteurs de désacétylase d'histone/pharmacocinétique , Epoxide hydrolase/antagonistes et inhibiteurs , Epoxide hydrolase/métabolisme , Rats , Rat Sprague-Dawley , Relation structure-activité , HumainsRÉSUMÉ
Neuropathic pain is a high-intensity pain that can be caused by compression, transection, injury, nerve infiltration and drug treatment of cancer. Furthermore, drug therapy has low clinical efficacy, many adverse effects and remission of painful symptoms. In this way, natural products derived from plants constitute a promising therapeutic alternative. Therefore, the aim of this study was to evaluate the antihyperalgesic effect of γ-terpinene (γ-TPN) e γ-terpinene in ß-cyclodextrin inclusion complexes (TPN/CD) on neuropathic pain induced by tumor cells. Complexation extended the effect time for another 5 h and daily treatment for six days with γ-TPN (50 mg/kg, p.o.) and γ-TPN/ß-CD (50 mg/kg, p.o.) significantly reduced (p < 0.001) the mechanical hyperalgesia induced by the administration of 2x106 sarcoma cells 180 in the around the sciatic nerve. In addition, the Grip and Rota-rod techniques demonstrated that there was no interference on the muscle strength and motor coordination of the animals, suggesting that the compound under study does not have central nervous system depressant effects at the doses used. Molecular docking studies demonstrate favorable binding energies between γ-TPN and ß-CD, and alpha-2 adrenergic, glutamatergic, opioid and cholinergic receptors. Thus, this study demonstrates the potential of terpinene complexation in controlling neuropathic pain induced by tumor cells.
Sujet(s)
Cyclohexane monoterpenes , Hyperalgésie , Monoterpènes , Névralgie , Cyclodextrines bêta , Animaux , Cyclodextrines bêta/composition chimique , Cyclodextrines bêta/administration et posologie , Névralgie/traitement médicamenteux , Hyperalgésie/traitement médicamenteux , Mâle , Monoterpènes/pharmacologie , Monoterpènes/composition chimique , Monoterpènes/administration et posologie , Souris , Analgésiques/pharmacologie , Analgésiques/composition chimique , Analgésiques/administration et posologie , Modèles animaux de maladie humaine , Nerf ischiatique/effets des médicaments et des substances chimiques , Nerf ischiatique/traumatismes , Lignée cellulaire tumorale , Simulation de docking moléculaire , Sarcome 180 de Crocker/traitement médicamenteux , Sarcome 180 de Crocker/anatomopathologieRÉSUMÉ
The presence of phenazopyridine in water is an environmental problem that can cause damage to human health and the environment. However, few studies have reported the adsorption of this emerging contaminant from aqueous matrices. Furthermore, existing research explored only conventional modeling to describe the adsorption phenomenon without understanding the behavior at the molecular level. Herein, the statistical physical modeling of phenazopyridine adsorption into graphene oxide is reported. Steric, energetic, and thermodynamic interpretations were used to describe the phenomenon that controls drug adsorption. The equilibrium data were fitted by mono, double, and multi-layer models, considering factors such as the numbers of phenazopyridine molecules by adsorption sites, density of receptor sites, and half saturation concentration. Furthermore, the statistical physical approach also calculated the thermodynamic parameters (free enthalpy, internal energy, Gibbs free energy, and entropy). The maximum adsorption capacity at the equilibrium was reached at 298 K (510.94 mg g-1). The results showed the physical meaning of adsorption, indicating that the adsorption occurs in multiple layers. The temperature affected the density of receptor sites and half saturation concentration. At the same time, the adsorbed species assumes different positions on the adsorbent surface as a function of the increase in the temperature. Meanwhile, the thermodynamic functions revealed increased entropy with the temperature and the equilibrium concentration.
Sujet(s)
Nanostructures , Thermodynamique , Adsorption , Nanostructures/composition chimique , Analgésiques/composition chimique , Graphite/composition chimique , Polluants chimiques de l'eau/composition chimique , Carbone/composition chimiqueRÉSUMÉ
Tropomyosin receptor kinases (Trks) are receptor tyrosine kinases activated by neurotrophic factors, called neurotrophins. Among them, TrkA interacts with the nerve growth factor (NGF), which leads to pain induction. mRNA-display screening was carried out to discover a hit compound 2, which inhibits protein-protein interactions between TrkA and NGF. Subsequent structure optimization improving phosphorylation inhibitory activity and serum stability was pursued using a unique process that took advantage of the peptide being synthesized by translation from mRNA. This gave peptide 19, which showed an analgesic effect in a rat incisional pain model. The peptides described here can serve as a new class of analgesics, and the structure optimization methods reported provide a strategy for discovering new peptide drugs.
Sujet(s)
Récepteur trkA , Récepteur trkA/antagonistes et inhibiteurs , Récepteur trkA/métabolisme , Animaux , Rats , Humains , Relation structure-activité , Découverte de médicament , Inhibiteurs de protéines kinases/pharmacologie , Inhibiteurs de protéines kinases/composition chimique , Inhibiteurs de protéines kinases/synthèse chimique , Analgésiques/pharmacologie , Analgésiques/composition chimique , Analgésiques/synthèse chimique , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Peptides cycliques/synthèse chimique , Mâle , Facteur de croissance nerveuse/métabolisme , Phosphorylation , Douleur/traitement médicamenteux , Rat Sprague-DawleyRÉSUMÉ
Transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel, which is considered a highly validated target for pain perception. Repeated activation with agonists to desensitize receptors or use the antagonists can both exert analgesic effects. In this work, two series of novel phenylpiperazine derivatives were designed, synthesized, and evaluated for the in vitro receptor inhibitory activity and in vivo analgesic activity. Among them, L-21 containing sulfonylurea group was identified with potent TRPV1 antagonistic activity and analgesic activity in various pain models. At the same time, L-21 exhibited low risk of hyperthermia side effect. These results indicated that L-21 is a promising candidate for further development of novel TRPV1 antagonist to treat pain.
Sujet(s)
Analgésiques , Pipérazines , Canaux cationiques TRPV , Canaux cationiques TRPV/antagonistes et inhibiteurs , Canaux cationiques TRPV/métabolisme , Pipérazines/composition chimique , Pipérazines/pharmacologie , Pipérazines/synthèse chimique , Animaux , Souris , Analgésiques/pharmacologie , Analgésiques/composition chimique , Analgésiques/synthèse chimique , Humains , Douleur/traitement médicamenteux , Relation structure-activité , Mâle , Cellules HEK293 , RatsRÉSUMÉ
The dorsal root ganglion (DRG) is the primary neuron responsible for transmitting peripheral pain signals to the central nervous system and plays a crucial role in pain transduction. Modulation of DRG excitability is considered a viable approach for pain management. Neuronal excitability is intricately linked to the ion channels on the neurons. The small and medium-sized DRG neurons are chiefly engaged in pain conduction and have high levels of TTX-S sodium channels, with Nav1.7 accounting for approximately 80% of the current. Voltage-gated sodium channel (VGSC or Nav) blockers are vital targets for the management of central nervous system diseases, particularly chronic pain. VGSCs play a key role in controlling cellular excitability. Clinical research has shown that Nav1.7 plays a crucial role in pain sensation, and there is strong genetic evidence linking Nav1.7 and its encoding gene SCN9A gene to painful disorders in humans. Many studies have shown that Nav1.7 plays an important role in pain management. The role of Nav1.7 in pain signaling pathways makes it an attractive target for the potential development of new pain drugs. Meanwhile, understanding the architecture of Nav1.7 may help to develop the next generation of painkillers. This review provides updates on the recently reported molecular inhibitors targeting the Nav1.7 pathway, summarizes their structure-activity relationships (SARs), and discusses their therapeutic effects on painful diseases. Pharmaceutical chemists are working to improve the therapeutic index of Nav1.7 inhibitors, achieve better analgesic effects, and reduce side effects. We hope that this review will contribute to the development of novel Nav1.7 inhibitors as potential drugs.
Sujet(s)
Canal sodique voltage-dépendant NAV1.7 , Bloqueurs de canaux sodiques voltage-dépendants , Humains , Canal sodique voltage-dépendant NAV1.7/métabolisme , Bloqueurs de canaux sodiques voltage-dépendants/pharmacologie , Bloqueurs de canaux sodiques voltage-dépendants/composition chimique , Bloqueurs de canaux sodiques voltage-dépendants/usage thérapeutique , Bibliothèques de petites molécules/composition chimique , Bibliothèques de petites molécules/pharmacologie , Bibliothèques de petites molécules/usage thérapeutique , Douleur cancéreuse/traitement médicamenteux , Douleur cancéreuse/métabolisme , Analgésiques/composition chimique , Analgésiques/pharmacologie , Analgésiques/usage thérapeutique , Animaux , Relation structure-activité , Gestion de la douleur/méthodes , Structure moléculaire , Tumeurs/traitement médicamenteux , Bloqueurs de canaux sodiques/pharmacologie , Bloqueurs de canaux sodiques/composition chimique , Bloqueurs de canaux sodiques/usage thérapeutiqueRÉSUMÉ
The novel cinnamic acid (CA) (H4-CA, H5-CA, and H7-CA) and caffeic acid (KA) (H4-KA, H5-KA, and H7-KA) hemorphin analogs have recently been synthesized and their trans isomers have been tested for antiseizure and antinociceptive activity. In the present study, the cis forms of these compounds were tested and compared with their trans isomers in seizure and nociception tests in mice. The cis-H5-CA and H7-CA compounds showed efficacy against psychomotor seizures, whereas the trans isomers were ineffective. Both the cis and trans KA isomers were ineffective in the 6-Hz test. In the maximal electroshock (MES) test, the cis isomers showed superior antiseizure activity to the trans forms of CA and KA conjugates, respectively. The suppression of seizure propagation by cis-H5-CA and the cis-H5-KA was reversed by a kappa opioid receptor (KOR) antagonist. Naloxone and naltrindole were not effective. The cis-isomers of CA conjugates and cis-H7-KA produced significantly stronger antinociceptive effects than their trans-isomers. The cis-H5-CA antinociception was blocked by naloxone in the acute phase and by naloxone and KOR antagonists in the inflammatory phase of the formalin test. The antinociception of the KA conjugates was not abolished by opioid receptor blockade. None of the tested conjugates affected the thermal nociceptive threshold. The results of the docking analysis also suggest a model-specific mechanism related to the activity of the cis-isomers of CA and KA conjugates in relation to opioid receptors. Our findings pave the way for the further development of novel opioid-related antiseizure and antinociceptive therapeutics.
Sujet(s)
Analgésiques , Anticonvulsivants , Acides caféiques , Cinnamates , Crises épileptiques , Animaux , Analgésiques/pharmacologie , Analgésiques/composition chimique , Analgésiques/synthèse chimique , Anticonvulsivants/pharmacologie , Anticonvulsivants/composition chimique , Anticonvulsivants/synthèse chimique , Souris , Mâle , Crises épileptiques/traitement médicamenteux , Cinnamates/pharmacologie , Cinnamates/composition chimique , Cinnamates/synthèse chimique , Cinnamates/usage thérapeutique , Acides caféiques/pharmacologie , Acides caféiques/composition chimique , Acides caféiques/usage thérapeutique , Acides caféiques/synthèse chimique , Peptides/pharmacologie , Peptides/composition chimique , Peptides/synthèse chimique , Peptides/usage thérapeutique , Simulation de docking moléculaire , IsomérieRÉSUMÉ
Multitarget strategies are essential in addressing complex diseases, yet developing multitarget-directed ligands (MTDLs) is particularly challenging when aiming to engage multiple therapeutic targets across different tissues. Here, we present a molecular transformer strategy, enhancing traditional MTDLs. By utilizing esterase-driven hydrolysis, this approach mimics the adaptive nature of transformers for enabling molecules to modify their pharmacological effects in response to the biological milieu. By virtual screening and biological evaluation, we identified KGP-25, a novel compound initially targeting the voltage-gated sodium channel 1.8 (Nav1.8) in the peripheral nervous system (PNS) for analgesia, and later the γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia. Our findings confirm KGP-25's dual efficacy in cellular and animal models, effectively reducing opioid-related side effects. This study validates the molecular transformer approach in drug design and highlights its potential to overcome the limitations of conventional MTDLs, paving new avenues in innovative therapeutic strategies.
Sujet(s)
Analgésiques , Esterases , Ligands , Analgésiques/pharmacologie , Analgésiques/composition chimique , Animaux , Humains , Esterases/métabolisme , Anesthésiques/pharmacologie , Anesthésiques/composition chimique , Récepteurs GABA-A/métabolisme , Récepteurs GABA-A/composition chimique , Conception de médicament , Souris , MâleRÉSUMÉ
ETHNOPHARMACOLOGICAL RELEVANCE: Plant vernacular names can provide clues about the popular use of a species in different regions and are valuable sources of information about the culture or vocabulary of a population. Several medicinal plants in Brazil have received names of medicines and brand-name products. AIM OF THE STUDY: The present work aimed to evaluate the chemical composition and pharmacological activity in the central nervous system of three species known popularly by brand names of analgesic, anti-inflammatory, antispasmodic, and digestive drugs. MATERIALS AND METHODS: Hydroethanolic extracts of Alternanthera dentata (AD), Ocimum carnosum (OC), and Plectranthus barbatus (PB) aerial parts were submitted to phytochemical analysis by HPLC-PAD-ESI-MS/MS and evaluated in animal models at doses of 500 and 1000 mg/kg. Mice were tested on hot plate, acetic acid-induced writing, formalin-induced licking, and intestinal transit tests. Aspirin and morphine were employed as standard drugs. RESULTS: The three extracts did not change the mice's response on the hot plate. Hydroethanolic extracts of AD and PB reduced the number of writhes and licking time, while OC was only effective on the licking test at dose of 1000 mg/kg. In addition, AD and OC reduced intestinal transit, while PB increased gut motility. CONCLUSIONS: Pharmacological tests supported some popular uses, suggesting peripheral antinociceptive and anti-inflammatory effects, while the phytochemical analysis showed the presence of several flavonoids in the three hydroethanolic extracts and steroids in PB, with some barbatusterol derivatives described for the first time in the species.
Sujet(s)
Amaranthaceae , Analgésiques , Anti-inflammatoires , Parasympatholytiques , Composés phytochimiques , Parties aériennes de plante , Extraits de plantes , Plectranthus , Animaux , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Analgésiques/pharmacologie , Analgésiques/composition chimique , Souris , Parasympatholytiques/pharmacologie , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/composition chimique , Mâle , Amaranthaceae/composition chimique , Plectranthus/composition chimique , Composés phytochimiques/pharmacologie , Composés phytochimiques/analyse , Douleur/traitement médicamenteux , Ocimum/composition chimique , Spectrométrie de masse en tandem , Brésil , Transit gastrointestinal/effets des médicaments et des substances chimiquesRÉSUMÉ
Investigation of the fruits of Rhododendron molle G. Don led to the isolation of three new grayanane-type diterpenoids, rhodomolleins LIV-LVI (1-3). The structures and absolute configurations of new compounds were fully elucidated by spectroscopic analysis and single-crystal X-ray diffraction, including HRESIMS, 1 D and 2 D NMR data. Compounds 1-3 were evaluated for analgesic activities utilizing an acetic acid-induced writhing test in mice. Compound 1 showed a significant antinociceptive effect with writhe inhibition rates of 72.9% and 100% at doses of 6 mg/kg and 20 mg/kg in mice, respectively. The binding mode of 1 to N-ethylmaleimide-sensitive factor (NSF, PDB: 6IP2) was explored by molecular docking, indicating the presence of hydrogen bond interactions which account for its analgesic activity.
Sujet(s)
Analgésiques , Diterpènes , Fruit , Rhododendron , Animaux , Diterpènes/pharmacologie , Diterpènes/composition chimique , Diterpènes/isolement et purification , Rhododendron/composition chimique , Analgésiques/pharmacologie , Analgésiques/composition chimique , Souris , Structure moléculaire , Fruit/composition chimique , Simulation de docking moléculaire , Mâle , Cristallographie aux rayons XRÉSUMÉ
Pain management following acute injury or post-operative procedures is highly necessary for proper recovery and quality of life. Opioids and non-steroidal anti-inflammatory drugs (NSAIDS) have been used for this purpose, but opioids cause addiction and withdrawal symptoms whereas NSAIDS have several systemic toxicities. Derivatives of the naturally occurring iboga alkaloids have previously shown promising behavior in anti-addiction of morphine by virtue of their interaction with opioid receptors. On this frontier, four benzofuran analogs of the iboga family have been synthesized and their analgesic effects have been studied in formalin induced acute pain model in male Swiss albino mice at 30â mg/kg of body weight dose administered intraperitoneally. The antioxidant, anti-inflammatory and neuro-modulatory effects of the analogs were analyzed. Reversal of tail flick latency, restricted locomotion and anxiogenic behavior were observed in iboga alcohol, primary amide and secondary amide. Local neuroinflammatory mediators' substance P, calcitonin gene related peptide, cyclooxygenase-2 and p65 were significantly decreased whereas the depletion of brain derived neurotrophic factor and glia derived neurotrophic factor was overturned on iboga analog treatment. Behavioral patterns after oral administration of the best analog were also analyzed. Taken together, these results show that the iboga family of alkaloid has huge potential in pain management.
Sujet(s)
Benzofuranes , Modèles animaux de maladie humaine , Inflammation , Nociception , Animaux , Souris , Mâle , Benzofuranes/pharmacologie , Benzofuranes/composition chimique , Benzofuranes/usage thérapeutique , Inflammation/traitement médicamenteux , Inflammation/métabolisme , Nociception/effets des médicaments et des substances chimiques , Douleur aigüe/traitement médicamenteux , Douleur aigüe/métabolisme , Analgésiques/pharmacologie , Analgésiques/composition chimique , Analgésiques/usage thérapeutiqueRÉSUMÉ
ETHNOPHARMACOLOGICAL RELEVANCE: Pain and inflammation are the most frequent reasons for which people seek medical care. Currently available analgesics against these conditions produce fatal adverse effects. NPK 500 capsules is an alternative herbal analgesic employed to treat dysmenorrhea, peptic ulcer and pain. NPK 500 is produced from Cassia sieberiana. A plant used in traditional medicine to treat pain and inflammation. AIM OF THE STUDY: This study reports the analysis, phytochemical characterization and mechanism of analgesic and anti-inflammatory activities of two NPK 500 capsules, called old and new NPK500 capsules (ONPK500 and NNPK500) respectively. MATERIALS AND METHODS: Physicochemical, organoleptic, GC-MS and LC-MS methods were employed to analyze the NPK 500 capsules. Analgesic activity was evaluated using tail immersion, Randall-Selitto and acetic acid induced writing tests. Anti-inflammatory activity was evaluated using carrageenan-induced rat paw inflammation. Additionally, pro-inflammatory mediators such as prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), cyclooxygenase 1 and 2 (COX-2 and COX-1) were quantified in the sera of the rats using Enzyme Linked Immunosorbent Assay (ELISA) kits. RESULTS: Thirteen major compounds were characterized in the NNPK 500 capsules via the GC-MS and LC-MS spectroscopies. Kaempferol was the major compound characterized in addition to physcion, ß-sitosterol 3-O-ß-D-glucopyranoside, betulinic acid and nine others. Physicochemical and organoleptic indices of the capsules were also derived for its authentication and quality control. Furthermore, NNPK 500 0.5-1.5 mg/kg p.o. produce significant (P < 0.5) analgesic activity (160-197%) higher than that of ONPK500 (109.8%) and Morphine (101%) in the tail immersion test. The analgesic activity of NNPK 500 0.5-1.5 mg/kg p.o. (171.0-258.3%) and ONPK 500 (179.5%) were also significant (P < 0.01) and higher than that of Aspirin (103.00%) in the Randall-Selitto test. Both capsules also demonstrated significant (P < 0.5) analgesic and anti-inflammatory activities in the acetic acid-induced writhing and carrageenan-indued paw edema tests respectively. The two NPK500 capsules also, significantly (P < 0.5) inhibited PGE2 and iNOS but not COX-2 and COX-1 in the carrageenan-indued paw edema test. CONCLUSION: These results show that NNPK 500 and ONPK 500 capsules possessed potent analgesic and anti-inflammatory activities via inhibition of PGE2 and iNOS as a result of their chemical constituents. NPK500 capsules thus, relief acute pain and inflammation without causing gastrointestinal, renal or hepatic injuries, since they did not inhibit COX-1.
Sujet(s)
Analgésiques , Anti-inflammatoires , Cassia , Dinoprostone , Dysménorrhée , Nitric oxide synthase type II , Animaux , Femelle , Souris , Rats , Analgésiques/pharmacologie , Analgésiques/usage thérapeutique , Analgésiques/composition chimique , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique , Capsules , Carragénane , Cassia/composition chimique , Cyclooxygenase 2/métabolisme , Dinoprostone/métabolisme , Dysménorrhée/traitement médicamenteux , Dysménorrhée/induit chimiquement , Oedème/traitement médicamenteux , Oedème/induit chimiquement , Nitric oxide synthase type II/métabolisme , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Extraits de plantes/usage thérapeutique , Rat Sprague-DawleyRÉSUMÉ
The endogenous opioid system regulates pain through local release of neuropeptides and modulation of their action on opioid receptors. However, the effect of opioid peptides, the enkephalins, is short-lived due to their rapid hydrolysis by enkephalin-degrading enzymes. In turn, an innovative approach to the management of pain would be to increase the local concentration and prolong the stability of enkephalins by preventing their inactivation by neural enkephalinases such as puromycin-sensitive aminopeptidase (PSA). Our previous structure-activity relationship studies offered the S-diphenylmethyl cysteinyl derivative of puromycin (20) as a nanomolar inhibitor of PSA. This chemical class, however, suffered from undesirable metabolism to nephrotoxic puromycin aminonucleoside (PAN). To prevent such toxicity, we designed and synthesized 5'-chloro substituted derivatives. The compounds retained the PSA inhibitory potency of the corresponding 5'-hydroxy analogs and had improved selectivity toward PSA. In vivo treatment with the lead compound 19 caused significantly reduced pain response in antinociception assays, alone and in combination with Met-enkephalin. The analgesic effect was reversed by the opioid antagonist naloxone, suggesting the involvement of opioid receptors. Further, PSA inhibition by compound 19 in brain slices caused local increase in endogenous enkephalin levels, corroborating our rationale. Pharmacokinetic assessment of compound 19 showed desirable plasma stability and identified the cysteinyl sulfur as the principal site of metabolic liability. We gained additional insight into inhibitor-PSA interactions by molecular modeling, which underscored the importance of bulky aromatic amino acid in puromycin scaffold. The results of this study strongly support our rationale for the development of PSA inhibitors for effective pain management.
Sujet(s)
Transduction du signal , Animaux , Relation structure-activité , Transduction du signal/effets des médicaments et des substances chimiques , Mâle , Souris , Structure moléculaire , Relation dose-effet des médicaments , Humains , Antigènes CD13/antagonistes et inhibiteurs , Antigènes CD13/métabolisme , Enképhalines/composition chimique , Enképhalines/métabolisme , Enképhalines/pharmacologie , Puromycine/pharmacologie , Puromycine/métabolisme , Puromycine/composition chimique , Analgésiques/pharmacologie , Analgésiques/composition chimique , Aminopeptidases/antagonistes et inhibiteurs , Aminopeptidases/métabolisme , RatsRÉSUMÉ
The development of multitarget opioid drugs has emerged as an attractive approach for innovative pain management with reduced side effects. In the present study, a novel hybrid peptide BNT12 containing the opioid and neurotensin (NT)-like fragments was synthesized and pharmacologically characterized. In acute radiant heat paw withdrawal test, intracerebroventricular (i.c.v.) administration of BNT12 produced potent antinociception in mice. The central antinociceptive activity of BNT12 was mainly mediated by µ-, δ-opioid receptor, neurotensin receptor type 1 (NTSR1) and 2 (NTSR2), supporting a multifunctional agonism of BNT12 in the functional assays. BNT12 also exhibited significant antinociceptive effects in spared nerve injury (SNI)-neuropathic pain, complete Freund's adjuvant (CFA)-induced inflammatory pain, acetic acid-induced visceral and formalin-induced pain after i.c.v. administration. Furthermore, BNT12 exhibited substantial reduction of acute antinociceptive tolerance, shifted the dose-response curve to the right by only 1.3-fold. It is noteworthy that BNT12 showed insignificant chronic antinociceptive tolerance at the supraspinal level. In addition, BNT12 exhibited reduced or no opioid-like side effects on conditioned place preference (CPP) response, naloxone-precipitated withdrawal response, acute hyperlocomotion, motor coordination, gastrointestinal transit, and cardiovascular responses. The present investigation demonstrated that the novel hybrid peptide BNT12 might serve as a promising analgesic candidate with limited opioid-like side effects.